ArticleEpidemiology and health2021
Controlling the drug-resistant tuberculosis epidemic in India: challenges and implications.
Article in Epidemiology and health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Prospective feasibility study of [68Ga]Gallium citrate PET/CT for treatment response assessment in spinal tuberculosis: exploratory comparison with follow-up [18 F]FDG PET/CT.Annals of nuclear medicine · 2026Article
- Pan-genomic analysis of the multi-drug resistant strains of Mycobacterium tuberculosis.World journal of microbiology & biotechnology · 2026Article
- Strengthening the National Reference Laboratory in the Republic of Congo: An Investment Imperative for Tuberculosis Diagnostics.Tropical medicine and infectious disease · 2026Article
- Assessment of post-pandemic NAAT-based diagnostic capacity among laboratories with COVID-19 testing resource investments in Indonesia.PloS one · 2026Article
- Autophagy in tuberculosis: advances, translational gaps, and the promise of host-directed therapies.Frontiers in cellular and infection microbiology · 2026Review
- Delays in tuberculosis diagnosis and treatment in India: A patient journey analysis from Mumbai and Patna during the COVID-19 Pandemic.PLOS global public health · 2026Article
- Reimagining tuberculosis elimination in India: diagnostics, drug resistance, and digital health strategies.Frontiers in epidemiology · 2026Review
- Strategies and Recent Advances in Tackling Antibacterial Resistance in India: A Comprehensive Narrative Review.Cureus · 2025Review
- Clinical and Epidemiological Profile of HIV TB Coinfection Among Adult Male and Female Population Across the City of Pune - A Cross-sectional Observational Study Protocol.Journal of pharmacy & bioallied sciences · 2025Article
- Bridging gaps in tuberculosis control: addressing cross-border challenges between India and Pakistan.Journal of clinical tuberculosis and other mycobacterial diseases · 2025Article
- Efficacy and safety data on pretomanid for drug-resistant TB.IJTLD open · 2025Review
- Global trajectory and spatiotemporal epidemiological landscape of multidrug-resistant tuberculosis of spanning 46 years (1990-2035): implications for achieving global end TB goals.Frontiers in public health · 2025Article
- Treatment outcomes among patients with isoniazid mono-resistant tuberculosis in Mumbai, India: A retrospective cohort study.Journal of clinical tuberculosis and other mycobacterial diseases · 2024Article
- Article
- Evaluation of Diagnostic Methods and Rifampicin Resistance in Pulmonary Tuberculosis: A Hospital-Based Study.Cureus · 2024Article
- Whole-genome sequencing of clinical isolates from tuberculosis patients in India: real-world data indicates a high proportion of pre-XDR cases.Microbiology spectrum · 2024Article
- Tracking multidrug resistant tuberculosis: a 30-year analysis of global, regional, and national trends.Frontiers in public health · 2024Article
- Double trouble: compounding effects of COVID-19 pandemic and antimicrobial resistance on drug resistant TB epidemiology in India.Frontiers in public health · 2023Article
- Snapshot ofGenes · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
India has a higher tuberculosis (TB) burden than any other country, accounting for an estimated one-fourth of the global burden. Drug-resistant tuberculosis (DR-TB) presents a major public health problem in India. Patients with DR-TB often require profound changes in their drug regimens, which are invariably linked to poor treatment adherence and sub-optimal treatment outcomes compared to drug-sensitive TB. The challenge of addressing DR-TB is critical for India, as India contributes over 27% of global DR-TB cases. In recent decades, India has been proactive in its battle against TB, even implementing a revised National Strategic Plan to eliminate TB by 2025. However, to achieve this ambitious goal, the country will need to take a multifaceted approach with respect to its management of DR-TB. Despite concerted efforts made by the National TB Elimination Program, India faces substantial challenges with regard to DR-TB care, especially in peripheral and resource-limited endemic zones. This article describes some of the major challenges associated with mitigating the growing DR-TB epidemic in India and their implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.